Xeno Diagnostics expands facility
We are excited to announce the expansion of the Xeno Diagnostics facility in Indianapolis, IN. The additional 2700 square feet of office and laboratory space will allow the expansion of our immuno-oncology program.
We are excited to announce the expansion of the Xeno Diagnostics facility in Indianapolis, IN. The additional 2700 square feet of office and laboratory space will allow the expansion of our immuno-oncology program.
Aim: Umbilical cord blood (UCB) sourced allografts are promising interventions for tissue regeneration. As applications of these allografts and regulations governing them continue to evolve, we were prompted to identify parameters determining their quality, safety, and regenerative potential…read more
Prosthetic arteriovenous grafts (AVGs) conventionally used for hemodialysis are associated with inferior primary patency rates and increased risk of infection compared with autogenous vein grafts. We tissue-engineered an AVG grown from neonatal human dermal fibroblasts entrapped in bovine fibrin gel that is then decellularized…read more
Xeno Diagnostics has added a mixed lymphocyte tumor cell assay to our list of services. The mixed lymphocyte tumor cell (MLTuC) is a method for generating T-lymphocytes that are cytotoxic to specific tumor cells. This assay offers a means to screen various pharmacological agents for their ability to enhance T-cell cytotoxicity to specific neoplasms. Click here to download.
The efficacy and immune-modulation of mesenchymal stem cells is well documented. The issue of obtaining mesenchymal stem cells without patient risk, extensive intra-operative procedure, cell manipulation or exposure of cells to harmful reagents remains an issue. This study was designed to test the viability, composition, and osteogenic potential of cells derived…read more.
Xeno Diagnostics has received an award for Laboratory Excellence following its most recent COLA inspection, making this the fourth consecutive inspection for Xeno to receive this award. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey with no citations…. read more
Genetically modified porcine models of pig-to-human xenotransplantation offer the most immediate answer to a growing shortage of available solid organs. Recently a modified porcine glycan model has been discovered that reduces human antibody binding to levels comparable with allograft standards. As this background provides an answer to the problem of acute humoral xenograft rejection (AHXR), it is important to consider the impact these modifications have on…read more
Short chain fatty acids (SCFA), products of microbial fermentation of dietary fiber, exert multiple metabolic effects in cells. Previously, we had demonstrated that soluble fiber influenced fat mass accumulation, gut microbial community structure and SCFA production in pigs…read more
Heat stress (HS) results from excessive heat load on animals such that all adaptive mechanisms used to dissipate the heat do not return the body to normal body temperature. In pigs, HS results in increased fat deposition compared with pair-fed animals in a thermoneutral environment…read more
Full length single chain (FLSC) is a novel HIV vaccine that presents conserved CD4i epitopes on HIV envelope. The constrained structure is achieved with single chain complexes of gp120 and CD4 fragments. FLSC elicits cross-reactive antibodies and heterologous protection against SHIV/SIV in three independent…read more
Xeno Diagnostics has again received an award for Laboratory Excellence following its most recent COLA inspection. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey.
Xeno Diagnostics, LLC, announced today that Dr. Daniel Wierda has joined Xeno as their new Director of Research and Development. Dan brings with him a great depth of experience in the area of immunotoxicology and cell-based assays. Prior to joining Xeno, Dan worked for 22 years at Eli Lilly and Company as a research scientist and toxicologist…read more
Soy oil is a major vegetable oil consumed in the US. A recently developed soybean variety produces oil with a lower concentration of a-linolenic acid, hence a higher (n-6)/(n-3) ratio, than regular soy oil. The study was conducted to determine the metabolic impact of the low a-linolenic acid containing soy oil…read more
Xeno Diagnostics, LLC has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is given only to laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey…read more
"*" indicates required fields
Copyright © 2021. All rights reserved.